The First International Conference on Vascular Targeting: Meeting overview

Cancer Research

Volumn 63, Issue 5, 2003, Pages 1144-1147

  Thorpe, Philip E ^a,d   Chaplin, David J ^b   Blakey, David C ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Oxigene Inc   (United States)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ADENOSINE TRIPHOSPHATE MU RAF PROTEIN; ANGIOGENESIS INHIBITOR; ANTIBODY; ANTINEOPLASTIC AGENT; CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; CYTOTOXIC AGENT; DNA; GADOLINIUM; GELONIN; HUMAN COAGULATION INDUCING PROTEIN TF; HYBRID PROTEIN; IMMUNOTOXIN; INTERLEUKIN 12; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TES 23; N ACETYLCOLCHINOL PHOSPHATE; NITRIC OXIDE SYNTHASE INHIBITOR; PROCOAGULANT; PS ANTIBODY; RAF PROTEIN; RICIN A; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY L19; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN; ZINOSTATIN;

ABDOMINAL PAIN; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ATAXIA; BLOOD FLOW; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PAIN; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; DRUG EFFECT; DRUG TARGETING; ENDOTHELIUM; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE THERAPY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; MALAISE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SLURRED SPEECH; SOLID TUMOR; TREMOR; TUMOR BLOOD FLOW; TUMOR CELL DESTRUCTION; VISUAL DISORDER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS;

EID: 0037373826     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Denekamp, J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev., 9: 267-282, 1990.
2. Denekamp, J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol., 66: 181-186, 1993.
3. Burrows, F. J., and Thorpe, P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA, 90: 8996-9000, 1993.
4. Burrows, F. J., and Thorpe, P. E. Vascular targeting: a new approach to the therapy of solid tumors. Pharmacol. Ther., 64: 155-174, 1994.
5. Hill, S. A., Lonergan, S. J., Denekamp, J., and Chaplin, D. J. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur. J. Cancer, 29A: 1320-1324, 1993.
6. Chaplin, D. J., and Horsman, M. R. The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiother. Oncol., 3, 0: 59-65, 1994.
7. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., and Thorpe, P. E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (Wash. DC), 275: 547-550, 1997.
8. Blakey, D. C., Westwood, F. R., Walker, M., Hughes, G. D., David, P. D., Ashton, S. E., and Ryan, A. J. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res., 8: 1974-1983, 2002.
9. Tozer, G. M., Kanthou, C., Parkins, C. S., and Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol., 83: 21-38, 2002.
10. Ching, L. M., Goldsmith, D., Joseph, W. R., Komer, H., Sedgwick, J. D., and Baguley, B. C. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res., 59: 3304-3307, 1999.
11. Siemann, D. W., and Rojiani, A. M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys., 53: 164-171, 2002.
12. Pedley, R. B., Hill, S. A., Boxer, G. M., Flynn, A. A., Boden, R., Watson, R., Dearling, J., Chaplin, D. J., and Begent, R. H. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res., 61: 4716-4722, 2001.
13. Griggs, J., Skepper, J. N., Smith, G. A., Brindle, K. M., Metcalfe, J. C., Hesketh, R. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am. J. Pathol., 160: 1097-1103, 2002.